Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPPC-doxorubicin
- Development stage
- Preclinical
- Lead developer
- National Yang Ming Chiao Tung University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
**LPPC-doxorubicin** is an investigational intravenous nanolipoplex formulation in which the anthracycline **doxorubicin** is encapsulated in a Lipo-PEG-PEI complex carrier. The LPPC carrier was designed to retain and slowly release doxorubicin, prolong systemic exposure, reduce clearance, and restrict apparent distribution relative to free doxorubicin in preclinical testing. Doxorubicin exerts antitumor activity principally through DNA intercalation and topoisomerase II inhibition, resulting in DNA damage and apoptosis. LPPC-doxorubicin was evaluated preclinically in HEC-1-A human endometrial cancer xenografts and showed antitumor activity; it is distinct from LPPC-Q7-DOX, which additionally contains the Q7 anticancer peptide.
- Other names
- LPPC-DOXLPPC-doxorubicinlipoplex-encapsulated doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on LPPC-doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPPC-doxorubicin.